Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] Administered as a '5 Days On - 2 Days Off' Oral Treatment in Advanced Small Cell Lung Cancer.

Trial Profile

Open Label Phase II Study on RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] Administered as a '5 Days On - 2 Days Off' Oral Treatment in Advanced Small Cell Lung Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Sep 2012

At a glance

  • Drugs Rubitecan (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 23 Jul 2008 Last checked against ClinicalTrials.gov record.
    • 16 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top